LBJ Family Wealth Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-25,604
Closed -$2.61M 24
2023
Q2
$2.61M Sell
25,604
-4,303
-14% -$407K 1.81% 11
2023
Q1
$2.72M Sell
29,907
-452
-1% -$26.5K 1.91% 11
2022
Q4
$1.15M Hold
30,359
0.86% 13
2022
Q3
$763K Hold
30,359
0.62% 16
2022
Q2
$923K Hold
30,359
0.69% 15
2022
Q1
$999K Hold
30,359
0.64% 15
2021
Q4
$801K Hold
30,359
0.47% 16
2021
Q3
$3.05M Hold
30,359
1.82% 11
2021
Q2
$4.3M Sell
30,359
-9
-0% -$1.02K 2.55% 10
2021
Q1
$3.03M Hold
30,368
1.91% 11
2020
Q4
$3.75M Hold
30,368
2.44% 10
2020
Q3
$2.96M Hold
30,368
2.24% 10
2020
Q2
$4.74M Hold
30,368
3.8% 10
2020
Q1
$4.38M Sell
30,368
-13,728
-31% -$2.65M 4.24% 9
2019
Q4
$9.45M Hold
44,096
6.54% 6
2019
Q3
$3.54M Hold
44,096
2.66% 10
2019
Q2
$3.71M Sell
44,096
-9,308
-17% -$804K 2.74% 10
2019
Q1
$4.56M Hold
53,404
2.57% 10
2018
Q4
$3M Sell
53,404
-7,371
-12% -$450K 2.63% 10
2018
Q3
$4.97M Sell
60,775
-29,425
-33% -$2.07M 3.81% 9
2018
Q2
$3.15M Hold
90,200
2.54% 10
2018
Q1
$1.85M Hold
90,200
1.53% 12
2017
Q4
$2.25M Hold
90,200
1.85% 12
2017
Q3
$2.81M Hold
90,200
2.39% 11
2017
Q2
$2.85M Hold
90,200
2.58% 10
2017
Q1
$2.04M Hold
90,200
1.94% 13
2016
Q4
$1.97M Buy
+90,200
New +$2.28M 1.96% 13

Other funds holding RETA

LBJ Family Wealth Advisors's RETA Position: Q3 2023 in Review

LBJ Family Wealth Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 25,604 shares — an estimated $2.61M sold.

LBJ Family Wealth Advisors first reported a position in RETA in Q4 2016 and held it in 27 quarters. The position peaked at $9.45M in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

  • LBJ Family Wealth Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
  • LBJ Family Wealth Advisors sold 25,604 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $2.61M.
  • LBJ Family Wealth Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2016 and held it in 27 quarters.
  • LBJ Family Wealth Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $9.45M in Q4 2019.
  • 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on LBJ Family Wealth Advisors's 13F filing for Q3 2023, filed 10 Oct 2023.